Related Experiment Video
Updated: Feb 17, 2026
Mouse Models of Epididymitis Induced by Pathogen-Associated Molecular Patterns
Published on: December 12, 2025
Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice
Maira Ablake1, Masahiro Itoh, Tetsushi Kaneko
1Department of Anatomy, Tokyo Medical University, Shinjuku 6-1-1, Shinjuku, Tokyo, Japan.
Abstract:
The effects of the treatment with the immunosuppressant deoxyspergualin on the development of experimental autoimmune orchitis were studied. The results showed that C3H/He mice immunized with testicular germ cells and treated daily with either 0.3 or 3 mg/kg body weight deoxyspergualin during days 15-20 post-immunization developed experimental autoimmune orchitis lesions with a significantly lower incidence and severity than did the control mice treated under the same experimental conditions with phosphate buffered saline (PBS). The effects of deoxyspergualin were clearly dose-dependent, and the higher dose of the drug also markedly reduced the degree of delayed type hypersensitivity responses against testicular germ cells. These data suggest that deoxyspergualin may be worthy of consideration for the prevention/treatment of human immunoinflammatory orchitis.
Insights
Deoxyspergualin treatment significantly reduced experimental autoimmune orchitis in mice. This immunosuppressant showed dose-dependent effects, suggesting potential for treating human immunoinflammatory orchitis.
Area of Science:
- Immunology
- Reproductive Medicine
- Pharmacology
Background:
- Experimental autoimmune orchitis (EAO) is an immunoinflammatory condition affecting testicular function.
- Understanding the role of immunosuppressants in modulating EAO is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of deoxyspergualin, an immunosuppressant, in preventing and treating experimental autoimmune orchitis.
- To determine the dose-dependent effects of deoxyspergualin on EAO development and related immune responses.
Main Methods:
- C3H/He mice were immunized with testicular germ cells to induce EAO.
- Mice received daily treatments of deoxyspergualin (0.3 or 3 mg/kg) or phosphate-buffered saline (PBS) from day 15 to 20 post-immunization.
- Incidence and severity of EAO lesions were assessed.
- Delayed type hypersensitivity (DTH) responses to testicular germ cells were measured.
Main Results:
- Deoxyspergualin treatment significantly reduced the incidence and severity of EAO lesions compared to PBS controls.
- The observed therapeutic effects were dose-dependent, with the higher dose showing greater efficacy.
- The higher dose of deoxyspergualin also markedly reduced DTH responses against testicular germ cells.
Conclusions:
- Deoxyspergualin demonstrates significant potential in mitigating experimental autoimmune orchitis.
- The dose-dependent efficacy suggests a promising therapeutic window for deoxyspergualin.
- Further consideration of deoxyspergualin for preventing or treating human immunoinflammatory orchitis is warranted.
